From: Emerging roles of m6A RNA modification in cancer therapeutic resistance
Target | Drug | Cancer | Effect | Ref. |
---|---|---|---|---|
METTL3 | Adenosine analogues | NA | Reduces RNA m6A | [170] |
UZH1a | AML | Suppress proliferation and viability of tumor cells in vitro | [171] | |
UZH2 | AML, prostate cancer | More potent anti-proliferative effects in vitro | [172] | |
STM2457 | AML | Anti-leukemia efficacy in vitro and in vivo | [173] | |
FTO | Rhein | AML | Anti-leukemia efficacyin vitro and in vivo | [159] |
MA2 | GBM | reduces GBM stem cell proliferation in vitro and tumor progression in mic | [160] | |
CHTB | NA | Increases RNA m6A | [161] | |
N-CDPCB | NA | Increases RNA m6A | [162] | |
R-2HG | AML, GBM | Anti-leukemia efficacy in vitro and in vivo, suppresses GBM in viro, synergizes with chemotherapeutic drugs | [86] | |
FB23-2 | AML | Anti-leukemia efficacy in vitro and in vivo | [163] | |
CS1 and CS2 | AML | potent anti-leukemic efficacy in mouse models, sensitize leukemia cells to T-cell cytotoxicity, overcomes immune evasion | [150] | |
Dac5 | Melanoma | Promotes activation and effector state of T cell, improving anti-PD1 blockade effects | [151] | |
FB23-13a | AML | Stronger anti-leukemia efficacy in vitro and in vivo | [164] | |
18,097 | Breast cancer | restrain in vivo growth and lung colonization | [165] | |
FTO-43 | GC, AML, GBM | Potent anti-tumor effects in mouse model | [166] | |
Compound C6 | Esophageal cancer | Anti-tumor efficacy in vitro and in vivo | [167] | |
AML | Anti-leukemia and improves anti-PD1 blockade efficacy | [169] | ||
ALKBH5 | ALK-04 | Melanoma | Improve anti-PD-1 therapy efficiency | [140] |
Compound 1 and 2 | AML | Anti-proliferative effects in specific AML cell lines | [174] | |
IGF2BP1 | BTYNB | Ovarian cancer | Anti-tumor efficacy in vitro and in vivo | [175] |